Home | DAIC

Visage introduces Visage 7, Cardiology Imaging and Visage 7 RadPath Hub

News | PACS

Visage Soars with CloudPACS at RSNA 2023

November 13, 2023 — Visage Imaging, Inc., a wholly owned subsidiary of Pro Medicus Ltd., has announced it will be ...

November 13, 2023

Research presented at AHA Scientific Sessions 2023 associates vMap’s use with significantly improved outcomes for unstable VT and surgical ablation of ventricular arrhythmias

News | AHA

Exciting New Applications of vMap for Ventricular Arrhythmias Highlighted at AHA 2023

November 13, 2023 — Vektor Medical, a pioneer in non-invasive arrhythmia analysis technology, is proud to highlight two ...

November 13, 2023

Ultromics, a leading health technology company at the forefront of detection of heart failure and its phenotypes, announces a significant development regarding the reimbursement code for its flagship product, EchoGo Heart Failure.

News | Heart Failure

CMS publishes final Clinical APC rule for Ultromics EchoGo Heart Failure

November 13, 2023 — Ultromics, a leading health technology company at the forefront of detection of heart failure and ...

November 13, 2023

Sponsored Content

Feature | Thrombectomy Devices

Redefining PE and VTE Intervention

Venous thromboembolism (VTE), and pulmonary embolism (PE) in particular, are among the most complex and dangerous acute ...

June 01, 2026

Results of a randomized trial presented today at the American Heart Association’s Scientific Sessions 2023, AHA 2023, which compared the effects of high-sodium and low-sodium diets on blood pressure in adults, found that following a low-sodium diet significantly lowered blood pressure in 70%-75% of participants in as little as one week

News | AHA

Reducing Sodium Intake Significantly Lowered Blood Pressure in as Little as One Week, Reports AHA 2023 Late-Breaking Science Abstract

November 11, 2023 — Results of a randomized trial presented today at the American Heart Association’s Scientific ...

November 11, 2023

Data from the randomized control trial will advance evidence for evaluation and treatment of heart disease by studying actual disease: atherosclerosis.

News | AHA

Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association AHA 2023 Scientific Sessions

November 11, 2023 — An announcement on partners to collaborate in the TRANSFORM trial was made today during the American ...

November 11, 2023

Getinge announced commercial availability of the iCast covered stent system in the United States

News | Peripheral Artery Disease (PAD)

Getinge Announces U.S. Commercial Availability of iCast Covered Stent System for Treatment of Iliac Arterial Occlusive Disease

November 10, 2023 —Getinge announced commercial availability of the iCast covered stent system in the United States for ...

November 10, 2023

Sponsored Content

Feature | Cardiac Imaging

Providing Clarity into CAD

Sponsored Content — According to the American Heart Association, cardiovascular disease is the leading cause of death in ...

March 13, 2026

Zerlasiran showed very significant and durable reductions in lipoprotein(a) of up to 99% Lp(a) levels remained around 90% lower than baseline at study endpoint

News | Cardiovascular Clinical Studies

Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease

November 10, 2023 — Silence Therapeutics plc, an experienced and innovative biotechnology company committed to ...

November 10, 2023

Experts from the Smidt Heart Institute at Cedars-Sinai will present on a variety of topics at AHA 2023. Photo by Cedars-Sinai.

News | Atrial Fibrillation

Cedars-Sinai Investigators to Unveil New Heart Research at AHA 2023

November 10, 2023 — Cardiologists, cardiothoracic surgeons and interventionalists from the Smidt Heart Institute at ...

November 10, 2023

News | Artificial Heart

Total Artificial Heart Developer BiVACOR Mechanical Engineer Receives Sezai Innovation Award at ISMCS Annual Conference

November 10, 2023 — BiVACOR, a clinical-stage medical device company developing the Total Artificial Heart (TAH), has ...

November 10, 2023

Sponsored Content

Feature | Nuclear Imaging

Cardiac PET/CT — A New Standard for Cardiac Imaging

Cardiac PET/CT represents a major advancement in cardiovascular diagnostics, offering significant clinical and ...

November 12, 2025

Further enhancing comprehensive trauma care solution

News | Artificial Intelligence

RapidAI Receives FDA Clearance of AI Module for Detection of Hemispheric Subdural Hematomas

November 9, 2023 — RapidAI, a global leader in developing artificial intelligence (AI) and technology workflow solutions ...

November 09, 2023

Clinical trial data released during VIVA 2023 Conference included results from a study involving the Veryan Medical BioMimics 3D Vascular Stent System.

News | VIVA

Final Round of Late-breaking Clinical Trial Results Announced at VIVA23

November 9, 2023 — The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular ...

November 09, 2023

The survey indicates the increased use of RPM to manage care both in clinics and home-based cardiac rehab settings

News | Remote Monitoring

New Cardiac Rehabilitation Survey Reveals 93% of Healthcare Providers Currently Utilize Remote Patient Monitoring Technology

November 9, 2023 — According to a recent survey of healthcare providers (HCPs), 93 percent of clinicians are currently ...

November 09, 2023

Sponsored Content

Feature

Intuitive Imaging Workflow System Offers Improved Efficiency, Flexibility

SPONSORED CONTENT — Studycast is a comprehensive imaging workflow system that allows healthcare professionals to work ...

June 17, 2025

News | TCT

Medinbox Debuts New Digital Education Product Suites for Interventional Ecosystem

November 9, 2023 — Medinbox, a global provider of video integrated collaboration systems for interventional rooms and ...

November 09, 2023

Recor Medical, Inc. and its parent company, Otsuka Medical Devices Co., Ltd. has announced that the U.S. Food and Drug Administration (FDA) has approved Recor’s Paradise Ultrasound Renal Denervation (RDN) system for the treatment of hypertension.

News | FDA

First FDA Approval of Renal Denervation System to Treat Hypertension Announced by Recor Medical and Otsuka Medical Devices

November 8, 2023 — Recor Medical, Inc. and its parent company, Otsuka Medical Devices Co., Ltd. has announced that the U ...

November 08, 2023

Agamon Health's Patient Adherence platform is aimed at raising standards of cardiovascular care

News | Artificial Intelligence

Agamon Health enters into know-how agreement with Mayo Clinic to close cardiology care gaps with generative AI

November 8, 2023 — Agamon Health is a healthcare technology company that uses Generative AI and workflow automation to ...

November 08, 2023